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Abstract We demonstrate that the differential effects Cbl and
oncogenic 70Z/3 Cbl have on Ca2+/Ras-sensitive NF-AT
reporters is partially due to their opposing ability to regulate
phospholipase CQ1 (PLCQ1) activation as demonstrated by
analysis of the activation of an NF-AT reporter construct and
PLCQ1-mediated inositol phospholipid (PI) hydrolysis. Cbl over-
expression resulted in reduced T cell receptor-induced PI
hydrolysis, in the absence of any effect on PLCQ1 tyrosine
phosphorylation. In contrast, expression of 70Z/3 Cbl led to an
increase in basal and OKT3-induced PLCQ1 phosphorylation and
PI hydrolysis. These data indicate that Cbl and 70Z/3 Cbl
differentially regulate PLCQ1 phosphorylation and activation.
The implications of these data on the mechanism of Cbl-mediated
signaling regulation are discussed.
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1. Introduction
Engagement of the T cell receptor (TCR) by antigen pre-
sented in the context of the major histocompatibility complex
triggers multiple biochemical cascades that ultimately lead to
T cell activation and proliferation. Two of the major path-
ways activated by TCR engagement are the Ras and phos-
pholipase CQ-1 (PLCQ1) pathways [1^4]. Although much is
known concerning the signaling cascades following Ras and
PLCQ1 activation, comparatively less is known about the link
between TCR-induced tyrosine kinase activation and the ac-
tivation of Ras and PLCQ1. Proteins that act as major sub-
strates for tyrosine phosphorylation immediately following
TCR engagement are likely to play an important role in signal
transduction. One such protein is the adapter Cbl.
The c-cbl protooncogene was identi¢ed as the cellular ho-
mologue of v-cbl, the transforming gene of the Cas NS-1
retrovirus [5,6]. Another oncogenic form of Cbl, 70Z/3 Cbl,
was isolated from a pre-B lymphoma and has an internal 17
amino acid deletion from amino acids 366^382 which results
in a protein that is hyperphosphorylated and transforming in
¢broblasts [7]. Cbl is a major substrate for tyrosine phosphor-
ylation following stimulation via a number of di¡erent recep-
tors including the T and B cell antigen-speci¢c receptors [8^
13] (for a complete review see [14]). Cbl is a complex protein
with multiple, diverse, protein interaction domains [6,15^20].
These diverse domains have been shown to regulate the inter-
action of Cbl with important signaling molecules, such as
Fyn, ZAP-70, Grb2, inositol phospholipid (PI)3K, Vav and
PLCQ1 [9,10,15,16,18,21^24].
Forced over-expression of Cbl has been shown to inhibit
signal transduction in various cellular systems. For example,
Cbl over-expression in mast cells inhibits the function of the
tyrosine kinase, Syk [25], while in ¢broblasts it leads to inhi-
bition of epidermal growth factor (EGF) receptor signaling
[26,27]. We have demonstrated that Cbl over-expression in-
hibits TCR-induced activation of the Ras/MAPK pathway
[28]. Furthermore, Sli-1, a Cbl homologue in Caenorhabditis
elegans, was shown to act as a negative regulator of the Ras
homologue, Let60, possibly by a¡ecting the function of Sem5,
a Grb2 homologue [29]. Taken together these studies suggest
that Cbl is a negative regulator of signal transduction.
Several recent studies have utilized reporter constructs
under the control of NF-AT elements to investigate the ability
of wild type (WT) Cbl and the oncoprotein, 70Z/3 Cbl, to
regulate signaling in T cells [30^32]. Optimal activation of
cis-regulatory NF-AT sites requires both Ras-inducible AP-1
factors, as well as activation of NF-AT transcription factors
by the calcium-sensitive phosphatase, calcineurin [33]. NF-AT
reporters can therefore be used to examine activation of both
the Ras and the Ca2 signaling pathways. The latter pathway
depends upon activation of PLCQ1 in T lymphocytes. Previous
studies indicated that over-expression of WT Cbl inhibits re-
ceptor-mediated NF-AT activation, while ectopic expression
of 70Z/3 Cbl leads to an increase in basal and ionomycin-
stimulated NF-AT activity [30,32]. Since we have previously
shown that Cbl over-expression inhibits TCR-induced Ras
activation, it is possible that the inhibitory e¡ect of Cbl
over-expression on NF-AT reporter activity is solely due to
inhibition of AP1 activation [28]. It was therefore of interest
to con¢rm whether Cbl and 70Z/3 Cbl regulate NF-AT acti-
vation exclusively through their ability to regulate Ras. Con-
trary to our expectations, this report presents data that indi-
cates that Cbl regulates TCR-induced PLCQ1 activation and
that the opposing e¡ects of WT Cbl and 70Z/3 Cbl on NF-AT
activity are due, in part, to their di¡erential ability to regulate
PLCQ1 phosphorylation and activation. Therefore, Cbl has
the ability to regulate events required for TCR-induced stim-
ulation of both the PLCQ1/Ca2 and Ras pathways.
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2. Materials and methods
2.1. Reagents
4L-Phorbol 12-myristate 13-acetate (PMA) was purchased from
Calbiochem (Nottingham, UK). The anti-CD3 monoclonal antibody
(OKT3) was from Ortho Biotech (Raritan, NJ, USA). The rabbit
anti-Cbl antibody was purchased from Santa-Cruz Biotechnology
(Santa Cruz, CA). The anti-phosphotyrosine antibody, 4G10, and
the mixed monoclonal anti-PLCQ1 were purchased from Upstate Bio-
technology (Lake Placid, NY). The anti-phosphotyrosine antibody,
PY54, was purchased from Transduction Laboratories (Lexington,
KY). The anti-hemagglutinin (HA) monoclonal antibody (12CA5)
and the anti-TCR antibody, C305 were used as ascites from the cor-
responding hybridoma. The C305 hybridoma was a gift of Dr. Arthur
Weiss (University of California, San Francisco, CA).
2.2. Plasmids
The pGreenLantern1-1 expression vector was from Life Technolo-
gies (Grand Island, NY). The NF-AT reporter vector (NF-AT-SEAP)
was provided by Dr. Gerald Crabtree (Stanford University Medical
School) [34]. Dr. Neil Clipstone (Northwestern University Medical
School) provided the activated calcineurin expression plasmid
(CNMUT2B). The Ras expression vector, pMEXneo-H-RasLys12,
was provided by Dr. Jorge Laborda (Center for Biological Evaluation
and Research, Food and Drug Administration) [35]. The HA-tagged
bovine PLCQ1 expression plasmid, pCIneo-PLCQ1(HA), and the hu-
man Cbl expression plasmid, pCI-Cbl, were described previously
[28,36]. The HA-tagged pJZEN/Neo 70Z/3 Cbl vector was a generous
gift of Dr. Wallace Langdon (University of Western Australia). To
generate non-HA tagged pCI-70Z/3 Cbl, the BlpI site of Cbl was used
to re-clone the 70Z/3 mutation into the non-HA tagged pCI-Cbl vec-
tor.
2.3. Cells and transfections
The Jurkat cell line used was a high CD3 expressing line generated
by Dr. Hana Golding (Center for Biological Evaluation and Research,
Food and Drug Administration). Cells were transfected as previously
described [37].
2.4. NF-AT-SEAP assays
Jurkat cells (107) were transfected with 7 Wg of NF-AT-SEAP and
the indicated expression vectors. Cells were stimulated and superna-
tants assayed for alkaline phosphatase activity as previously described
[28].
2.5. Cell sorting, labeling and analysis of inositol phosphates
Cells transfected with pGreenLantern1-1 and the indicated expres-
sion vectors were rested for 24 h. Live cells were recovered from a
Ficoll gradient and sorted on a Becton/Dickinson FACStar Plus. Ino-
sitol phosphate generation was measured as described [38]. For all
transfection experiments, the data were internally normalized for the
amount of total myo-[2-3H]inositol incorporation and expressed as the
percent change from untransfected cells. Data from three separate
experiments were analyzed by ANOVA and di¡erences within each
group were compared by t-test.
2.6. Stimulation, immunoprecipitation
For TCR stimulation, cells were activated with either (1) the anti-
TCR antibody, C305 (1:10 dilution of supernatant), or (2) the anti-
CD3 antibody, OKT3, for 2 min at 10 Wg/107 cells, or cells were
coated with 10 Wg/107 cells of OKT3 F(abP)2 for 15 min at 4‡C,
washed, and activated with 50 Wg/107 cells of a⁄nity-puri¢ed goat
antibody to mouse IgG (Kirkegaard and Perry, Gaithersburg, MD)
for 2 min. Post-nuclear lysates were immunoprecipitated with the
indicated antibodies. For anti-phosphotyrosine immunoprecipitations,
samples were boiled in 1% SDS, diluted to 0.1% SDS in 1Ulysis
bu¡er, immunoprecipitated, and proteins eluted with 100 mM phe-
nyl-phosphate, prior to SDS^PAGE and Western blot analysis.
3. Results
3.1. Cbl over-expression inhibits TCR-induced NF-AT
activation
Consistent with a previous observation [31], cells over-ex-
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pressing Cbl demonstrate approximately a 70% decrease in
TCR-induced NF-AT activity compared to control cells
(Fig. 1A). Because Cbl over-expression inhibits TCR-induced
AP-1 activation [28] which is required for optimal activity of
the NF-AT-SEAP reporter, the decrease in OKT3-induced
NF-AT-SEAP activity in Cbl over-expressing cells could be
due to inhibition of AP-1 activation. To overcome the inhib-
itory e¡ect Cbl has on TCR-induced AP-1 activation, cells
were activated either with a combination of OKT3 and the
phorbol ester, PMA, or a combination of OKT3 and a con-
stitutively active Ras protein, RasLys12. Both PMA and
RasLys12 stimulate AP-1 activity in a TCR-independent man-
ner which is una¡ected by Cbl over-expression [28]. Therefore,
PMA and RasLys12 will bypass any inhibitory e¡ect of Cbl
over-expression on AP-1 activation, while TCR cross-linking
with OKT3 will activate the PLCQ1/Ca2 pathway with ensu-
ing NF-AT transcriptional activation. Any reduction in NF-
AT-SEAP activity observed under these experimental condi-
tions will be due to an inhibition of TCR-induced activation
of NF-AT transcription factors through the PLCQ1/Ca2
pathway. As shown in Fig. 1A,B, Cbl over-expressing cells
stimulated with OKT3 and PMA or OKT3 and RasLys12
maintain a 70% decrease in NF-AT-SEAP activation com-
pared to control cells. These data indicate that Cbl over-ex-
pression can inhibit activation of NF-AT transcription fac-
tors.
Because the translocation of NF-AT transcription factors
to the nucleus is controlled by calcineurin activity, we next
determined if Cbl over-expression acts upstream or down-
stream of calcineurin. To this end we utilized an activated
calcineurin construct (CNMUT2B) that leads to the constitu-
tive dephosphorylation and nuclear translocation of NF-AT
independent of TCR signaling. Jurkat cells were transiently
transfected with NF-AT-SEAP together with CNMUT2B
and either pCI-neo or pCI-Cbl. Because optimal activation
of the NF-AT-SEAP reporter still requires AP-1 activation
even in the presence of activated calcineurin, activation of
AP-1 was accomplished by stimulation with OKT3 or PMA.
PMA was used as a TCR-independent and Cbl-insensitive
Fig. 1. Cbl over-expression regulates the PLCQ1/Ca2 pathway up-
stream of Ca2 mobilization. A: Jurkat cells were transfected with
7 Wg of NF-AT-SEAP and 5 Wg of either pCI-Cbl or pCI-neo. After
24 h in culture, transfected cells were left untreated or stimulated
with immobilized OKT3 (20 Wg/well), immobilized OKT3 plus PMA
(10 nM), or PMA alone. Supernatants were collected and assayed
for alkaline phosphatase activity. The mean þ S.D. of triplicate sam-
ples is shown. B: Jurkat cells were transfected with 7 Wg of NF-AT-
SEAP, 10 Wg of pMEXneo-H-RasLys12 and 5 Wg of either pCI-Cbl
or pCI-neo. Cells were cultured for 24 h and either left untreated or
stimulated with OKT3. Supernatants were assayed for SEAP activ-
ity. Shown is the mean þ S.D. of triplicates. C: Jurkat cells were
transfected with 7 Wg of NF-AT-SEAP, 0.5 Wg of CNMUT2B and
5 Wg of either pCI-Cbl or pCI-neo. After 24 h, the cells were either
left untreated or stimulated with OKT3 or PMA as indicated.
Supernatants were assayed for SEAP activity. Shown is the
mean þ S.D. of triplicates. D: Cells were transfected with the indi-
cated constructs as in A and treated with the indicated stimuli.
6
Fig. 2. Cbl over-expression inhibits TCR-induced phosphoinositide hydrolysis. A: Jurkat cells were transfected with 2 Wg of the pGreenLan-
tern1-1 expression vector along with 10 Wg of pCI-neo, pCI-Cbl, or an HA-tagged pCI-70Z/3. The data were normalized as the percent change
from untransfected cells. Shown is the mean þ S.D. of three experiments. B: Western blot analysis of Jurkat cells that were transfected with
20 Wg pCI-neo, pCI-Cbl, or an HA-tagged pCI-70Z/3. Membranes were probed with an anti-Cbl antibody.
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activator of AP-1. As shown in Fig. 1C, stimulation with
CNMUT2B and PMA resulted in no inhibition of NF-AT-
SEAP activity in Cbl over-expressing cells. As expected,
OKT3-induced NF-AT-SEAP activity was inhibited by Cbl
over-expression even in the presence of CNMUT2B because
of Cbl-mediated inhibition of AP-1 activation. No PMA-in-
ducible NF-AT activity over background was observed after
transfection of a WT calcineurin construct or the vector con-
trol for CNMUT2B (data not shown). These data indicate
that Cbl does not a¡ect events regulated by calcineurin and
does not directly interfere with the activity of NF-AT tran-
scription factors.
Recently, two studies have shown that 70Z/3 Cbl augments
the activity of NF-AT reporter constructs in unstimulated or
ionomycin-stimulated T cells [31,32] and we have also found
that 70Z/3 Cbl augments NF-AT activity in unstimulated T
cells (Fig. 1D). These reports suggest that this augmentation
may be due to activation of Ras and AP1 activity in these
cells [31,32]. However, these reports are con£icting on the
e¡ect 70Z/3 Cbl has on OKT3-induced NF-AT activation.
Although we have often seen decreases in OKT3-induced
NF-AT activation upon expression of 70Z/3, our results
have been variable and inconclusive (Fig. 1D and data not
shown). Interestingly, an increase in PMA induced NF-AT
activation can be seen in 70Z/3 expressing cells (Fig. 1D),
suggesting that 70Z/3 Cbl may also be able to augment NF-
AT activity by synergizing with PMA-induced Ras activation
via an increase in the activity of the PLCQ1/Ca2 pathway.
3.2. Cbl regulates events required for optimal PLCQ1 activity
These data demonstrate that Cbl over-expression can a¡ect
NF-AT activation by inhibiting events that lead to calcineurin
activation. In addition, 70Z/3 Cbl appears to augment NF-AT
activation in PMA-treated cells. We therefore questioned
whether Cbl could regulate events upstream of Ca2 mobili-
zation by directly a¡ecting PLCQ1 activation. The activation
of PLCQ1 results in PI hydrolysis which generates the second
messengers diacylglycerol and 1,4,5 triphosphate which con-
trol protein kinase C activity and Ca2 mobilization, respec-
tively. To directly assess PLCQ1 activation, PI hydrolysis was
analyzed in the fraction of cells which were transiently trans-
fected with Cbl. Jurkat cells were co-transfected with the
pGreenLantern1-1 expression vector, which encodes a form
of green £uorescent protein (GFP), and either pCI-neo or
pCI-Cbl. Transfected cells were then isolated by positive sort-
ing on a £uorescence activated cell sorter (FACS). Positive
(transfected) and negative (untransfected) cells were then la-
beled with myo-[3H]inositol and stimulated with OKT3 in the
presence of lithium chloride to block inositol phosphate phos-
phatases. The results demonstrate that, while transfection with
pCI-neo results in no change in PI hydrolysis, Cbl over-ex-
pression results in approximately a 40% decrease in OKT3-
induced PLCQ1 activity as assessed by PI hydrolysis
(P = 0.004) (Fig. 2A). Cbl over-expression, however, did not
a¡ect the inositol phosphate level of non-activated cells. This
decrease in OKT3-induced PI hydrolysis was observed when
6
Fig. 3. Cbl over-expression does not a¡ect TCR-induced PLCQ1 ty-
rosine phosphorylation. A: Jurkat cells were transfected with 5 Wg
of HA-tagged pCI-PLCQ1 and 10 Wg of either pCI-Cbl or pCI-neo.
Cells were either left unstimulated or stimulated with OKT3 F(abP)2
for 2 min. Anti-HA immunoprecipitates were resolved by SDS^
PAGE and immunoblotted with an anti-phosphotyrosine antibody
(4G10). The membranes were then stripped and re-probed with
anti-HA. WCL (0.5U106/lane) were probed with anti-Cbl. B: Jurkat
cells, transfected with 2 Wg of pGreenLantern1-1 and 10 Wg of pCI-
Cbl, were sorted by FACS. Cbl-transfected (Cbl) and untrans-
fected (Cbl3) cells were left unstimulated or stimulated with OKT3.
Samples were then immunoprecipitated with the anti-phosphotyro-
sine antibody, PY54, and immunoblotted with anti-PLCQ1 mixed
monoclonal antibodies or anti-Cbl. WCL were probed with anti-
PLCQ1 or anti-Cbl.
FEBS 23480 23-3-00
L.J. Graham et al./FEBS Letters 470 (2000) 273^280276
Cbl over-expressing cells were compared to either untrans-
fected (negatively sorted) control cells or positively sorted cells
transfected with the empty vector, pCI-neo. These data indi-
cate that Cbl regulates a step that is required for optimal
PLCQ1 activity.
While Cbl over-expression led to a 70% decrease in NF-AT
activity, we only observed a 40% decrease in inositol phos-
phate generation. This discrepancy is explained by the non-
linear relationship between inositol 1,4,5-trisphosphate and
calcium mobilization [39]. Furthermore, there appears to be
a non-linear relationship between calcium levels and calci-
neurin phosphatase activity as well as between calcineurin
activity and IL-2 production [4]. Based on these reports, small
changes in inositol phosphate generation would be predicted
to lead to substantial changes in NF-AT activity.
We next investigated the e¡ect of 70Z/3 Cbl on PLCQ1
activity. Jurkat cells were transfected with pCI-70Z/3 or
pCI-neo and the pGreenLantern1-1 plasmid and sorted on
the basis of GFP expression. Expression of the 70Z/3 Cbl
construct resulted in a small but signi¢cant increase in PI
hydrolysis in both unstimulated (P = 0.019) and OKT3-stimu-
lated (P = 0.014) cells when compared with control cells (Fig.
2A). The expression of Cbl and 70Z/3 Cbl were comparable,
ruling out that the di¡erential e¡ects on PLCQ1 activity were
due to di¡erences in the expression levels of each construct
(Fig. 2B). These data also rule out the possibility that the
inhibition of PLCQ1 activity seen with Cbl over-expression is
due to a transfection artifact and suggest that 70Z/3 Cbl can
augment NF-AT activation by increasing PLCQ1 activity.
3.3. Cbl over-expression has no e¡ect on TCR-induced PLCQ1
tyrosine phosphorylation
PLCQ1 activation is a multi-step process that involves tyro-
sine-phosphorylation of PLCQ1 [40,41]. To determine whether
Cbl over-expression was inhibiting TCR-induced tyrosine
phosphorylation of PLCQ1, Jurkat cells were transiently trans-
Fig. 4. Cbl over-expression does not a¡ect the time-course of TCR-induced PLCQ1 tyrosine phosphorylation. A: Jurkat cells were transfected
with 5 Wg of HA-tagged pCI-PLCQ1 and 10 Wg of either pCI-Cbl or pCI-neo as indicated. Cells were either left unstimulated or stimulated
with OKT3 F(abP)2 for the indicated amount of time. Anti-HA immunoprecipitates were resolved by SDS^PAGE and immunoblotted with an
anti-phosphotyrosine antibody (4G10). WCL were ¢rst probed with anti-HA to detect transfected PLCQ1-HA. Subsequent to this they were
stripped and probed for Cbl expression. The extent of PLCQ1 phosphorylation of the anti-HA immunoprecipitates was quantitated using a
phosphorimage analyzer (ImageQuant Software) and normalized either to total PLCQ1-HA (B) or to peak phosphorylation seen at 2 min (C).
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fected with a HA-tagged PLCQ1 construct (pCI-PLCQ1) and
either pCI-Cbl or pCI-neo. No di¡erence was seen in TCR-
induced PLCQ1 tyrosine phosphorylation between cells over-
expressing Cbl and vector control cells, as determined by anti-
phosphotyrosine Western blot analysis of anti-HA immuno-
precipitates from unstimulated and OKT3 stimulated cells
(Fig. 3A). The over-expression of Cbl was con¢rmed by
anti-Cbl Western blot analysis of whole cell lysates (WCL).
To ensure that the over-expression of PLCQ1 in these experi-
ments was not overcoming the ability of Cbl to regulate a step
involved in PLCQ1 tyrosine phosphorylation, we also investi-
gated the e¡ect of Cbl on the tyrosine phosphorylation of
endogenous PLCQ1. Jurkat cells were transfected with the
pGreenLantern1-1 expression vector and pCI-Cbl. Trans-
fected (GFP) and untransfected (GFP3) cells were then se-
lected by £uorescence sorting and either left unstimulated or
stimulated with OKT3. The degree of PLCQ1 and Cbl tyrosine
phosphorylation was determined by anti-PLCQ1 and anti-Cbl
Western blot analysis of anti-phosphotyrosine immunopreci-
pitates (Fig. 3B). To ensure that the immunoprecipitation of
PLCQ1 was not due to secondary interactions with other pro-
teins, lysates were boiled in lysis bu¡er containing 1% SDS
prior to dilution and immunoprecipitation. Therefore, any
phosphorylated PLCQ1 immunoprecipitated under these con-
ditions is due to a direct recognition by the immunoprecipi-
tating antibody. As expected, Cbl over-expression resulted in
a substantial increase in the amount of immunoprecipitated
tyrosine phosphorylated Cbl. No di¡erence however, was ob-
served in the degree of PLCQ1 tyrosine phosphorylation in Cbl
over-expressing cells compared to the negatively sorted, un-
transfected control cells (Fig. 3B). Furthermore, no di¡erence
was observed in the kinetics of PLCQ1 tyrosine phosphory-
lation over a 10 min time course of stimulation, at which
point PLCQ1 phosphorylation has returned to near baseline
levels (Fig. 4). This was true when PLCQ1 phosphorylation
was calculated as a ratio with total PLCQ1-HA in WCL
(Fig. 4B) or as a percent of the maximum response at 2 min
(Fig. 4C). These data indicate that Cbl over-expression does
not a¡ect TCR-induced PLCQ1 tyrosine phosphorylation.
To examine the e¡ect of expression of 70Z/3 Cbl on PLCQ1
tyrosine phosphorylation, Jurkat cells were transiently trans-
fected with pCI-PLCQ1 and either pCI-neo or pCI-70Z/3.
Anti-phosphotyrosine Western blot analysis of anti-HA im-
munoprecipitates was used to determine the degree of
PLCQ1 tyrosine phosphorylation. The results shown in Fig.
5 demonstrate that 70Z/3 Cbl increased both resting and
OKT3-stimulated PLCQ1 tyrosine phosphorylation. These re-
sults are consistent with the increase in PLCQ1 activity seen in
70Z/3 Cbl-expressing cells and indicate that 70Z/3 Cbl aug-
ments both the phosphorylation levels and activity of PLCQ1
in T cells.
4. Discussion
PLCQ1 activation requires tyrosine phosphorylation, trans-
location to the plasma membrane and interaction with the
substrate, PtdIns(4,5)P2 [40,42]. Although the events that reg-
ulate each of the steps involved in PLCQ1 activation are still
unclear, activation of TCR-proximal Src kinases and ZAP-70
together with the adapters LAT and SLP-76 are required for
PLCQ1 activation [36,43^45]. There are several possible mech-
anisms that could explain the ability of Cbl over-expression to
inhibit the PLCQ/Ca2 pathway. One possibility that has been
previously suggested is that Cbl can negatively regulate the
ZAP-70 tyrosine kinase [46]. This hypothesis is based on stud-
ies demonstrating that Cbl over-expression negatively regu-
lates the activity of the ZAP-70 related kinase, Syk [25],
that the PTB domain of Cbl binds to a negative regulatory
site of ZAP-70 [47,48], that exogenous Cbl expression blocks
NF-AT activation induced by ZAP-70 over-expression [47,48],
and that the kinetics of phosphorylation of the ZAP-70 sub-
strates, LAT and SLP-76 are altered in thymocytes from Cbl
knockout mice [49]. However, no di¡erence has been noted in
the phosphorylation pattern or enzymatic activity of ZAP-70
after exogenous expression of Cbl or 70Z/3 Cbl [48]. In addi-
tion, our data indicate that PLCQ1 phosphorylation, which is
known to be dependent on ZAP-70 activity [44], is una¡ected
by Cbl over-expression, arguing against an inhibition of ZAP-
70 as the predominant mechanism of Cbl regulation of the
PLCQ1/Ca2 pathway. Furthermore, because Cbl over-expres-
sion does not alter the kinetics of PLCQ1 phosphorylation, our
results also argue against the recruitment of a phosphatase as
the mechanism of Cbl inhibition of the PLCQ/Ca2pathway.
Cbl appears to regulate the ligand-induced ubiquitination
and degradation of the EGF receptor and the colony stimu-
lating factor-1 (CSF-1) receptor [50,51]. This is further sup-
ported by the recent ¢nding that the RING ¢nger domain of
Cbl can interact with UbcH7, a ubiquitin-conjugating enzyme
[52]. Cbl and UbcH7 synergistically promote the ligand-in-
duced ubiquitination of the EGF receptor, while 70Z/3 Cbl,
which has a mutation in the RING ¢nger domain and does
not interact with UbcH7, reduces ligand-induced UbcH7-
mediated ubiquitination of the EGF receptor [52]. Thus, Cbl
may negatively regulate EGF or CSF-1 receptor signaling by
promoting the ubiquitin-mediated internalization and degra-
Fig. 5. 70Z/3 Cbl expression augments TCR-induced PLCQ1 tyrosine
phosphorylation. Jurkat cells, transiently transfected with 10 Wg of
an HA-tagged PLCQ1 and 10 Wg of either pCI-neo or non-HA-
tagged pCI-70Z/3 Cbl, were left unstimulated or activated with the
anti-TCR antibody, C305. Lysates were immunoprecipitated with
anti-HA, and immunoblotted with an anti-phosphotyrosine antibody
(4G10). The membrane was then stripped and re-probed with anti-
HA to show the amount of immunoprecipitated PLCQ1. WCL were
immunoblotted for 70Z/3 Cbl expression with an anti-Cbl antibody.
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dation of these receptors, while 70Z/3 Cbl may augment sig-
naling by inhibition of this physiologic event [50^52].
The TCR also undergoes activation-induced ubiquitination
[53]. The signi¢cance of TCR-ubiquitination has not been
established and the role, if any, that Cbl plays in regulating
TCR ubiquitination and degradation have yet to be examined.
However, the ability of Cbl to regulate PLCQ1 activity cannot
be fully explained by increased ubiquitination and degrada-
tion of signaling molecules. Although ubiquitination of TCR
components can be observed within 5 min of receptor cross-
linking [53], no e¡ect of Cbl over-expression on the extent or
time-course of TCR-induced PLCQ1 phosphorylation and no
decrease in the total amount of PLCQ1 in WCL was observed.
Although these data do not rule out a role for Cbl in the
ubiquitination of TCR components, they indicate that the
decrease in PLCQ1 activity observed in Cbl over-expressing
cells is not due to increased degradation of PLCQ1 or other
proteins required for its phosphorylation.
We have previously suggested that Cbl may participate in
or regulate the formation of a multi-protein activation com-
plex and that the over-expression of Cbl in T cells disrupts the
physiologic stoichiometry of this complex leading to the for-
mation of incomplete complexes that are incapable of activat-
ing downstream signaling pathways [28]. If Cbl regulates the
formation of an activation complex, it is doing so at a point
that does not a¡ect the ability of PLCQ1 to associate with the
speci¢c kinase(s) that phosphorylates it. We have recently
shown that the amino-terminal Src-homology (SH) 2 domain
(SH2 (N) domain) of PLCQ1 is required for both immuno-
receptor-induced phosphorylation and activation of PLCQ1,
while its carboxy-terminal SH2 (SH2 (C)) and SH3 domains
are required for full activation, but are dispensable for TCR-
induced PLCQ1 phosphorylation [36,54]. Interestingly, Cbl
constitutively interacts with GST-fusion proteins encompass-
ing the SH3 domain of PLCQ1 [24], and in a phosphorylation-
dependent manner with GST-fusion proteins encompassing
the PLCQ1 SH2 domains [9]. Cbl-mediated blocking of the
function of either the PLCQ1 SH3 or SH2(C) domain could
result in a decrease in the activity of PLCQ1, without altering
its phosphorylation pattern. We are currently investigating
whether the ability of Cbl to interact with any of the SH-
domains of PLCQ1 is required for its ability to regulate
PLCQ1activation.
Interestingly, recent studies on another cbl family member,
cbl-b, indicate that cbl-b does not regulate either the PLCQ1
or the Ras pathway. Instead it appears to be a negative reg-
ulator of Vav1 phosphorylation [55,56]. These data, taken
together with those from our laboratory, suggest that di¡erent
Cbl family members may regulate unique signaling pathways.
Future studies on the di¡erential ability of Cbl proteins to
regulate Vav1 activation will be needed to con¢rm this hy-
pothesis.
In addition to 70Z/3 Cbl, v-Cbl has been shown to be
oncogenic [7,57] and a third Cbl variant was recently de-
scribed as being involved in gastrointestinal tumorigenesis
[58]. The oncogenic potential of these Cbl variants may be
due to their ability to compete with the physiologic inhibitory
function of endogenous Cbl [48]. Alternately, the transform-
ing forms of Cbl may induce a positive signal in a non-com-
petitive manner [31], possibly by inducing the activation of
signaling steps unique from those regulated by WT Cbl.
This latter mechanism is suggested by the unique e¡ect of
70Z/3 Cbl in increasing PLCQ1 phosphorylation in both un-
stimulated and OKT3-stimulated T cells, compared to the
lack of e¡ect that over-expression of WT Cbl had on PLCQ1
phosphorylation. Further studies will elucidate the signaling
events associated with 70Z/3 Cbl as they pertain to the mech-
anism of transformation by this and other Cbl variants.
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